番茄视频

Time to radiographic progression doubled with ¹⁷⁷Lu-PSMA-617

Amivantamab-based regimens improved oncologic outcomes, but with more side effects

Adjuvant alectinib reduces disease-free survival hazard by 76%

Still some unanswered questions about benefit over other drug regimens, expert says

After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus

PFS doubled and OS improved, driven by mismatch repair-deficient disease

Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy

Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care

Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses

Strategies involving immunotherapy, induction chemo move the needle for first time in decades

Two randomized studies demonstrate significantly improved PFS against standard regimens

Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy

Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation

Durvalumab plus olaparib, or alone, paired with chemo boosts PFS in DUO-E trial